Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: XFOR

X4 Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for XFOR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 12:28 UTC.

What X4 Pharmaceuticals, Inc. does

The company is a biopharmaceutical firm developing treatments for rare hematology diseases, with mavorixafor as its primary asset—an oral, small-molecule drug that acts as a selective antagonist of the CXCR4 chemokine receptor. The company's first commercially approved product is XOLREMDI (mavorixafor), which received FDA accelerated approval for treating WHIM syndrome, a rare combined primary immunodeficiency and chronic neutropenic disorder, in patients 12 years of age and older.

Summarized from X4 Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-42.51%
Debt/equity0.48

Revenue, margins & earnings

FY2024: net loss $37M on revenue $3M$3MFY2024FY2025: net loss $79M on revenue $35M$35MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-19
  • 2026-10-19Executive ChairmanPurchase4,600$11.9K
  • 2026-10-05Chief Financial OfficerSale-11,767$33.7K
  • 2026-08-13Executive ChairmanSale-47,436$210.8K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does X4 Pharmaceuticals, Inc. do?

The company is a biopharmaceutical firm developing treatments for rare hematology diseases, with mavorixafor as its primary asset—an oral, small-molecule drug that acts as a selective antagonist of the CXCR4 chemokine receptor.

When did XFOR last file with the SEC?

X4 Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-01. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 12:28 UTC. This page is also available as JSON at /api/data?ticker=XFOR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for XFOR and 5,000+ tickers.

Create a free account — keep XFOR
For your agent
GET /api/data?ticker=XFOR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt